Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

Fast -9% ohne irgendeinen Grund? Wie geht sowas

Null effekt.

A project led by PCA SKIN, a Colgate-Palmolive brand, will see MatTek, a part of the BICO Group, send their product EpiDermFT skin tissues to the International Space Station. MatTek Life Sciences, a BICO company, announced today that their tissues will be used as part of an experiment sponsored by the ISS National Lab and led by PCA SKIN, aboard the International Space Station to explore the effects of microgravity on human skin. Historical data has shown that during their time in a microgravity environment, astronauts experience thinning, dry skin, comparable to the normal effects of aging on Earth. “We want to take the opportunity to explore the unique conditions of microgravity and how that impacts skin health and develop products that can better meet our consumer's skin health needs,” said Joanna Wu, PhD, one of Colgate-Palmolive’s principal investigators on the project. “MatTek Life Sciences is a partner of choice because their full thickness 3D tissue, EpiDermFT, is a robust lab-grown skin model that can very well mimic real human skin.” MatTek’s EpiDermFT tissues are living, lab-grown human skin samples that react to external conditions and stimuli in the same way as skin on the human body. The skin samples will be exposed to microgravity conditions for several days aboard the ISS, then frozen until their return to Earth. Investigators will then conduct analysis and compare findings to parallel experiments performed on the ground to evaluate the effects of microgravity on human skin biology. “The lab-grown skin samples going to space are identical in structure and genetics to the skin samples kept on the ground, which allows scientists the ability to observe any potential changes to the tissues exposed to microgravity,” said Alex Armento, president and CEO of MatTek. “We’re always thrilled to be a part of projects like this one and to see how our technology, combined with innovative thinking from partners like Colgate-Palmolive, positively impacts human health.” The experiment will travel to the ISS aboard Northrop Grumman’s 17th commercial resupply services mission, contracted by NASA, in its Cygnus spacecraft no earlier than February 19, 2022, from NASA’s Wallops Flight Facility in Virginia.

😂👍

Spaß Jungs Langfristig bin ich definitiv überzeugt

Haha Wenn ich in Zukunft mal bisschen Geld loswerden will, einfach in bico investieren

Auf bico ist sozusagen verlass.

Und morgen freuen wir uns über 14

Haben uns immerhin die 15 zurückerkämpft 😄

Hab jetzt meinen EK bei 16,40. Mal sehen was kommt 😂

😂👍

Ich öffne die App und sehe bico mal wieder um die 4% im Minus. Alles normal also

Wieder mal echt einstiegskurse heute…🤪

Wenigstens wieder die 16 zurückerobert, so traurig es auch klingt 😅

Ich glaube diese brutalen Schwankungen zeigen die kommenden Tage bis zum 23.02 haha

CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies. CollPlant and CELLINK will explore the use of CELLINK's next-generation high throughput extrusion bioprinters for the future commercial production of CollPlant's regenerative breast implants, addressing a $2.8 Bn market Today, CELLINK, a BICO Group company (Nasdaq Stockholm:BICO) and a global leader in developing 3D bioprinting technologies which is expected to bridge the current gap and allow unlimited supply of life saving organs and CollPlant Biotechnologies (Nasdaq:CLGN) a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced they have signed a collaboration agreement. Under this collaboration, CELLINK’s high-throughput, multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant's 3D bioprinted regenerative breast implants, addressing a current market size of $2.8 billion, with 2.2 million procedures performed annually worldwide. CollPlant has successfully produced prototypes of 3D bioprinted implants designed to regenerate breast tissue, and is currently evaluating these implants in a series of preclinical studies. Comprised of CollPlant’s rhCollagen and other biological components, the regenerative implants aim to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer. In contrast with current approaches, CollPlant’s regenerative implants are designed to degrade over time to be replaced by new, naturally grown breast tissue. CELLINK, a global leader in bioprinting, is well positioned to support CollPlant’s in their large-scale bioprinting production process through the use of its printers and technical expertise, addressing biofabrication challenges. “We are thrilled to be working with a partner who shares our values and passion to create the future of health. We look forward to making an impact in the breast implant industry but also to develop a long-lasting relationship with CollPlant characterized by advancements in the wider field of tissue engineering and regenerative medicine” said Cecilia Edebo, CEO CELLINK. “We are very pleased to enter into the collaboration with CELLINK, a recognized leader in development of 3D bioprinting solutions for the life-science industry,” said CollPlant's CEO, Yehiel Tal. “We believe CELLINK's high throughput bioprinters and biofabrication expertise will help us move toward the successful commercialization of our technology and to deliver a much-needed solution to patients around the world”.